干扰素α1b与α2b治疗慢性丙型肝炎的最小成本分析

发布时间：2018-04-18 00:27

本文选题：干扰素αb + 干扰素αb　；参考：《中国药房》2016年23期

【摘要】：目的:比较干扰素α1b与α2b治疗慢性丙型肝炎的经济性。方法:采用回顾性研究方法,选择114例接受干扰素治疗的慢性丙型肝炎患者,将其中采用干扰素α1b治疗的60例作为A组,采用干扰素α2b治疗的54例作为B组,比较两组患者的丙型肝炎病毒(HCV)-RNA转阴率、丙氨酸转氨酶(ALT)复常率和不良反应发生率,并进行药物经济学分析。结果:A组患者治疗4、12、24、36、48周时的HCV-RNA转阴率分别为55.00%、71.67%、63.33%、61.67%、65.00%,B组患者在上述各时间的HCV-RNA转阴率分别为64.81%、66.67%、62.96%、55.56%、61.11%,组间比较差异均无统计学意义(P0.05);治疗结束时,A组患者的ALT复常率为95.23%,B组为96.10%,组间比较差异无统计学意义(P0.05);两组患者各种不良反应发生率比较,差异均无统计学意义(P0.05),故采用最小成本法进行药物经济学分析。A组的治疗成本为13 216.56元,B组为7 929.60元,B组的成本明显低于A组;敏感度分析得到同样的结果。结论:干扰素α2b治疗慢性丙型肝炎较干扰素α1b更为经济。
[Abstract]:Objective: to compare the economic efficiency of interferon 伪 1b and 伪 2b in the treatment of chronic hepatitis C.Methods: a retrospective study was carried out in 114 patients with chronic hepatitis C treated with interferon, 60 of whom were treated with interferon 伪 1b as group A and 54 as group B treated with interferon 伪 2b.The rates of HCV seroconversion, alanine aminotransferase (alt) reversion and adverse reactions were compared between the two groups, and the pharmacoeconomic analysis was carried out.Results at 48 weeks after treatment, the HCV-RNA negative conversion rate of group A was 55.00 and 71.67, respectively. The rate of ALT conversion in group B was 64.81and 64.81and 66.6762.9655.565.51, respectively. There was no significant difference between the two groups (P 0.05); at the end of the treatment, the ALT recovery rate of patients in group A was 95.2323.96.10, there was no significant difference between the two groups (P 0.05); the incidence of various adverse reactions in the two groups was higher than that in the control group.There was no significant difference between the two groups, so the cost of treatment in group A was 13 216.56 yuan and that in group B was 7 929.60 yuan, which was significantly lower than that in group A, and the sensitivity analysis showed the same result.Conclusion: interferon 伪 2b is more economical than interferon 伪 1b in the treatment of chronic hepatitis C.
【作者单位】：成都市公共卫生临床医疗中心;
【基金】：国家科技重大专项课题(No.2012ZX10005004-003)
【分类号】：R512.63

【相似文献】